Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. files reports and updates with the U.S. Securities and Exchange Commission (SEC) as a foreign private issuer with Class A ordinary shares listed on Nasdaq under APLM and public warrants under APLMW. These filings, which include Form 20-F annual reports and multiple Form 6-K current reports, provide detailed insight into the company’s clinical-stage oncology business, financial condition, capital structure and governance. On this page, you can review Apollomics’ SEC filings alongside AI-generated summaries that help explain key points in accessible language.
What Apollomics reports in its filings
Filings describe Apollomics as a clinical-stage biopharmaceutical or biotechnology company focused on oncology therapies, with a lead program in vebreltinib (APL-101), a selective c-Met inhibitor for non-small cell lung cancer and other tumors with MET alterations. The company’s reports outline its broader pipeline, including APL-122 and APL-102, and discuss program decisions such as the winding down of the uproleselan (APL-106) program after a Phase 3 bridging trial in China did not show favorable benefit.
Financial statements included in these filings detail research and development expenses, administrative expenses, impairment of intangible assets, net losses and equity or deficit positions over multiple periods. Liquidity discussions highlight Apollomics’ dependence on collaboration payments and financing transactions, including PIPE financings and upfront fees under its LaunXP agreement, and describe risks if expected payments are delayed or not received.
Governance, capital structure and warrants
Form 6-K reports document changes in the board of directors and executive management, the composition of board committees, and the appointment and resignation of directors. They also describe corporate actions such as the 1-for-100 reverse share split of Class A ordinary shares, adjustments to warrant terms and exercise prices, and Nasdaq listing compliance developments. For holders or analysts of APLMW warrants, these filings explain how the reverse split affected the number of shares issuable upon exercise and the revised exercise price.
Using AI summaries for faster review
Because SEC filings can be lengthy and technical, this page pairs Apollomics’ original documents with AI-powered summaries that highlight key disclosures, such as clinical program status, material agreements, PIPE subscription terms, liquidity risks and changes in control or governance. You can quickly identify items related to oncology trial outcomes, collaboration disputes, reverse share splits, and the company’s assessment of its ability to continue as a going concern, then drill down into the full text of 20-F, 6-K and related exhibits for deeper analysis.
Apollomics Inc. director Hong-Jung Chen filed an amended initial ownership report detailing current equity holdings. The filing lists 1,000 restricted stock units, each representing one Class A Ordinary Share, with 500 units vesting on June 15, 2026 and 500 on September 15, 2026. Chen also holds options over 2,290 Class A Ordinary Shares at an exercise price of $75.00 per share and options over 2,028 shares at $6.20 per share, plus warrants over 304 underlying shares at an adjusted exercise price of $1,150.00 per full share. Direct holdings also include 3,120 Class A Ordinary Shares.
Apollomics Inc.'s Chief Financial Officer Peter Kuan-How Lin reported an automatic share disposition related to equity compensation. On the vesting of restricted stock units, 3,582 Class A Ordinary Shares were withheld to cover tax obligations at $15.85 per share. After this tax-withholding event, Lin directly holds 12,318 Class A Ordinary Shares. This was not an open-market sale but a routine mechanism tied to RSU vesting.
Apollomics Inc. director Jan Chen-Huan has filed an amended ownership report showing equity awards and share holdings. The filing lists 1,000 Restricted Stock Units, each representing a contingent right to receive one Class A Ordinary Share. These RSUs are scheduled to vest in two equal installments of 500 shares on June 15, 2026 and September 15, 2026. The filing also reports direct ownership of 1,000 Class A Ordinary Shares following the reported positions.
Apollomics Inc. director Tsai Hsien-Shu reports equity holdings consisting of restricted stock units and common shares. The filing shows 1,000 restricted stock units, each representing a contingent right to receive one Class A Ordinary Share at an exercise price of $0.00 per share.
These restricted stock units will vest in two equal installments of 500 shares on June 15, 2026 and September 15, 2026. The filing also lists direct ownership of 1,000 Class A Ordinary Shares following the reported holdings.
Apollomics Inc. Chief Financial Officer LIN PETER KUAN-HOW reported his equity holdings in an amended Form 3. He holds restricted stock units representing 20,000 Class A Ordinary Shares and 15,900 Class A Ordinary Shares directly. The restricted stock units will vest in two equal installments of 10,000 shares each on June 15, 2026 and September 15, 2026.
Apollomics Inc. director and CEO Chen Hung-Wen has updated his reported equity holdings. The filing shows direct ownership of 143,334 Class A Ordinary Shares and indirect ownership of 763,028 Class A Ordinary Shares through King Regent Management Limited, where he is the sole director and shareholder and has voting and dispositive power.
He also holds Restricted Stock Units representing a contingent right to receive 10,000 Class A Ordinary Shares at an exercise price of $0.0000 per share. These RSUs are scheduled to vest in two equal tranches of 5,000 shares on June 15, 2026 and September 15, 2026. Mr. Chen disclaims beneficial ownership of the securities held by King Regent Management Limited except to the extent of his pecuniary interest.
Apollomics Inc. director CHU YI-AN reports equity holdings consisting of restricted stock units and related Class A Ordinary Shares. The filing shows 1,000 restricted stock units, each representing a contingent right to receive one Class A Ordinary Share at an exercise price of $0.0000 per share.
According to the disclosure, these restricted stock units are scheduled to vest with respect to 500 shares on June 15, 2026 and 500 shares on September 15, 2026. Following this reporting, the position includes 1,000 Class A Ordinary Shares tied to this award, all held as direct ownership.
Apollomics Inc. chief operating officer Chen Yi-Kuei filed an amended initial ownership report detailing his equity interests. He directly holds 10,000 Class A Ordinary Shares and 10,000 restricted stock units, each representing a right to one Class A Ordinary Share. The restricted stock units will vest in two equal tranches of 5,000 shares on June 15, 2026 and September 15, 2026. In addition, entities associated with him, including Maxpro Investment Co., Ltd., hold 101,248 Class A Ordinary Shares and warrants linked to 3,823 underlying Class A Ordinary Shares at an adjusted exercise price of $1,150.00 per full share, and he disclaims beneficial ownership except to the extent of his pecuniary interest.
Apollomics Inc. director Huang Ya-Chi has reported current equity holdings in the company. The filing shows direct ownership of 1,500 restricted stock units, each representing a contingent right to receive one Class A Ordinary Share. These restricted stock units are scheduled to vest in three equal installments of 500 shares on May 17, 2026, August 17, 2026 and November 17, 2026. The exercise price for the underlying shares is listed as $0.0000 per share. In addition, Huang Ya-Chi directly holds 500 Class A Ordinary Shares following the reported positions.
Apollomics Inc. executive Yi-Kuei (Alex) Chen has reported beneficial ownership of approximately 5.3% of the company’s Class A ordinary shares. The position totals 115,171 shares when including 100 shares held directly, 101,248 shares held through Maxpro Investment Co., Ltd., 3,823 shares issuable from warrants held by Maxpro, and 10,000 restricted stock units granted as compensation.
The filing states that 5,000 RSUs vested on February 17, 2026, with another 5,000 scheduled to vest on May 17, 2026, and that this vesting pushed Chen’s beneficial ownership above the 5% threshold. Chen indicates the shares are held for investment purposes and may be increased or reduced over time, while continuing to act in his role as Chief Operating Officer and director.